Synairgen completes a successful equity placing to fund the company’s trial for COVID-19 patients
Synairgen plc has raised US$17.6 million to fund the company’s trial for COVID-19 patients.
Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the company uses in vitro and ex vivo models to progress opportunities into clinical development. The biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Synairgen on its oversubscribed equity fundraising to fund the company’s trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, manufacture of the drug and to strengthen the company’s balance sheet.
Talk to the deal team
Related deals
Winking Studios Limited completes a secondary fundraising of US$20 million
Winking Studios has successfully raised US$20 million to fund its business strategy and future plans, such as strategic acquisitions, alliances and joint ventures as well as secondary or dual listings, to grow the group’s market share and broaden its customer base globally.
Learn moreFRP Advisory Group plc has finalized a successful secondary placing
FRP Advisory Group plc has completed a fundraising. The book was oversubscribed and approximately £20.4 million (US$33 million) of shares were sold by certain directors and partners of FRP to new and existing institutional investors at 128 pence per ordinary share.
Learn moreLeika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn more